Glasgow-based Nebu-Flow said it has secured an additional $5.9 million of investment to accelerate the next generation of inhaled drugs for patients with respiratory disorders.

The company said its nebulizer platform has been developed “to provide a number of advantages over existing technologies.”

The funding round was led by SCVC, a UK-based venture capital firm that invests in early-stage deep tech spinouts, and was supported by Scottish Enterprise, Foresight WAE Technology, SIS Ventures, Ascension, and Conduit EIS Impact Fund.

Nebu-Flow is a former spinout from the University of Glasgow.

Nebu-Flow CEO and co-founder Elijah Nazarzade  said: “Our mission is to revolutionize respiratory drug delivery.

“The investment accelerates our development activities to position the company for inhalation delivery of RNA-based formulations.

“We now look forward to the final product development and commercialization stages, with the support of SCVC and our other investors …

“Essentially, our technology provides new opportunities for targeted drug delivery to the lungs as well as drug delivery to the cardiovascular and central nervous systems.

“We are engaged with a number of partners in the UK and North America who are currently trialling the product as we prepare for the regulatory approval stage.”

SCVC Managing Partner Harry Destecroix said: “We are deeply impressed by the team’s achievement of its technical and commercial milestones to date, demonstrating their capability and readiness for the next phase in healthcare innovation.

“This investment underscores our confidence in Nebu-Flow’s groundbreaking nebulisation technology, which is poised to transform respiratory drug delivery, improve health and deliver impact.”